BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2023

Dec 20, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2023-12-19

Reporting Person: Stonehouse Jon P (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-19	Common Stock	F	14089	$6.05	Disposed	1114770	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	10000	Indirect
Common Stock	10000	Indirect

Footnotes

F1: Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person.